474381-67-4

Upstream product

• 5459-58-5 cyanoacetic acid butyl ester 
• 1074-12-0 phenylglyoxal hydrate 
• 98-86-2 acetophenone 

Downstream Products

• 474381-73-2 3-chloro-5-phenylpyridazine-4-carbonitrile 
• 1376604-14-6 methyl 3-oxo-5-phenyl-2,3-dihydropyridazine-4-carboxylate 
• 1376604-24-8 2-(3,5-diphenylpyridazin-4-yl)-4-(prop-1-en-2-yl)oxazole 
• 1376604-23-7 2-(2-(3,5-diphenylpyridazin-4-yl)oxazol-4-yl)propan-2-ol 
• 1181352-98-6 3-oxo-5-phenyl-2,3-dihydropyridazine-4-carboxylic acid 
• 1376604-22-6 2-(3, 5-diphenylpyridazin-4-yl)-4-vinyloxazole 
• 1376604-21-5 1-(2-(3,5-diphenylpyridazin-4-yl)oxazol-4-yl)ethanol 
• 1376604-20-4 1-(2-(3,5-diphenylpyridazin-4-yl)oxazol-4-yl)ethanone 
• 1376604-19-1 4-(bromomethyl)-2-(3,5-diphenylpyridazin-4-yl)oxazole 
• 1376604-18-0 (2-(3,5-diphenylpyridazin-4-yl)oxazol-4-yl)methanol 
• 1376604-17-9 N-(1-hydroxypropan-2-yl)-3,5-diphenylpyridazine-4-carboxamide 
• 1376604-16-8 methyl 2-(3,5-diphenylpyridazine-4-carboxamido)-3-hydroxypropanoate 
• 1376604-15-7 C₁₇H₁₁ClN₂O 
• 1258614-99-1 methyl 3-chloro-5-phenylpyridazine-4-carboxylate 

Relevant academic research and scientific papers

METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5 -containing GABAA receptor agonist in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

A regioselective one-pot, three component synthesis of 6-Aryl-4-cyano-3(2H) -pyridazinones in water

A series of 4-cyano-3(2H)-pyridazinones bearing different aryl substituents in the 6-position of the pyridazinone ring was synthesized regioselectively using a novel efficient one-pot three component reaction of alkyl 2-cyanoacetates with arylglyoxals in the presence of hydrazine hydrate at room temperature in water. CSIRO 2010.

Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases

Pyrazolopyridazine 1a was identified in a high-throughput screening carried out by BASF Bioresearch Corp. (Worcester, MA) as a potent inhibitor of CDK1/cyclin B and shown to have selectivity for the CDK family. Analogues of the lead compound have been syn